Case Study On The Role Of Circulation Tumor-infilting Lymphocytes In The Treatment Of Lung Cancer

Background: Lung carcinoma is one of malignant tumors to human health worldwide.Lung cancer is the leading cause of cancer death among men and the second leading cause of cancer death among women worldwide.For several years,surgery,chemotherapy,radiotherapy and targeted therapy have been widely used clinically.Nevertheless,the overall survival(OS)rate of lung cancer still remains unacceptable.Nowadays,the revolution of lung cancer managements is changing the situation.So it is fair to conclude that treatment with immune checkpoint inhibitors(ICIs)will become the backbone of lung cancer therapy in the near future.Circulation tumor infiltrating lymphocytes(CTIL)are a type of cell infiltrative and antigenic in peripheral blood,including T cells,B cells,and NK cells.Numerous studies have demonstrated that CTILs have been associated with different human tumors.The clinical treatment results are consistent with good results.In recent years,a large number of experimental groups have carried out whole genome sequencing of lung cancer,and screened out many genes that are differentially expressed in the development of lung cancer.These genes play a role in regulating the development of lung cancer.Despite the discovery of many genes that are differentially expressed in liver cancer,many genes that play an important regulatory role have not yet been discovered.Objective: This study was to investigate the role of CD28 and CD27 monoclonal antibodies in CTIL in the immunotherapy of lung cancer patients,and the expression changes of related cells in peripheral blood of patients with lung cancer,as well as the development of lung cancer screening by high-throughput sequencing technology.The specific genes that play a role in providing new targets for the diagnosis and treatment of lung cancer.Method:1.Peripheral blood mononuclear cells(PBMCs)were isolated from peripheral blood of patients with lung cancer.They were labeled with specific antibodies and magnetic beads.The cells were cultured in vitro and the cells were returned to the patient for clinical treatment effect.2.Peripheral blood mononuclear cells(PBMCs)from peripheral blood of patients with lung cancer were isolated and analyzed by labeling specific antibodies,magnetic bead sorting,and flow cytometry analysis of patient T cells,B cell CD28+,and CD27+ cells.Changes to detect changes in their immune levels.3.High-throughput sequencing of PBMC,CD28+,and CD27+ cells in peripheral blood from patients with lung cancer was performed to screen for differentially expressed genes.The RT-PCR,Real time-PCR and other experimental techniques were used to verify the expression of the differentially expressed genes.Results: 1.According to clinical treatment CT feedback results,patients with LD001 have significantly reduced lung tumors after treatment;patients' lung tumor size is negatively correlated with overall treatment time,that is,tumor size decreases as the number of treatments increases.the trend of;2.Flow analysis results showed that the proportion of CD3+ T cells,CD4+ T helper cells,CD8+ T cell cytotoxic T cells,CD28+ cells,CD27+ cells,and CD56+ NK cells in the CD28 and CD27 groups was significantly increased.The impact was on an upward trend,with significant differences,and some with extremely significant differences.3.High-throughput sequencing technology screened specific genes C5orf17,CAHM,DSCR9,PSMG3-AS1,LINC00346,LINC00216,and TTTY10.The final results from the validation experiment were obtained in the PBMC group and the CD27 and CD28 groups of LD001 patients.Compared with the C5orf17 gene,the expression of C5orf17 gene was decreased,and there was a significant difference.The expression of CAHM gene increased significantly.The expression of the PSMG3-AS1 gene in the CD27 group was significantly higher than that in the PBMC group,showing extremely significant differences.This also verified the experimental results of sequencing.To determine its role in the development of lung cancer,so as to provide new ideas and new targets for gene therapy for lung cancer.Conclusion: CTIL immunotherapy,combined with CD28 and CD27 monoclonal antibody technology,has a good therapeutic effect in the treatment of lung cancer,and can exhibit a high response rate and prolonged overall survival in cancer patients.High-throughput sequencing technology screened and verified that genes C5orf17,CAHM,and PSMG3-AS1,which are abnormally expressed in CD28 and CD27 in the PBMC group of LD001 patients,can provide assistance in the research of gene therapy for lung cancer.